全文获取类型
| 收费全文 | 172787篇 |
| 免费 | 7193篇 |
| 国内免费 | 378篇 |
专业分类
| 耳鼻咽喉 | 2331篇 |
| 儿科学 | 5289篇 |
| 妇产科学 | 4097篇 |
| 基础医学 | 24854篇 |
| 口腔科学 | 5563篇 |
| 临床医学 | 9966篇 |
| 内科学 | 38373篇 |
| 皮肤病学 | 4636篇 |
| 神经病学 | 14022篇 |
| 特种医学 | 4368篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 20251篇 |
| 综合类 | 838篇 |
| 一般理论 | 27篇 |
| 预防医学 | 20121篇 |
| 眼科学 | 4495篇 |
| 药学 | 13442篇 |
| 中国医学 | 677篇 |
| 肿瘤学 | 7007篇 |
出版年
| 2023年 | 893篇 |
| 2022年 | 627篇 |
| 2021年 | 2807篇 |
| 2020年 | 1573篇 |
| 2019年 | 3033篇 |
| 2018年 | 5214篇 |
| 2017年 | 3311篇 |
| 2016年 | 3318篇 |
| 2015年 | 3684篇 |
| 2014年 | 4102篇 |
| 2013年 | 6198篇 |
| 2012年 | 10642篇 |
| 2011年 | 11213篇 |
| 2010年 | 5578篇 |
| 2009年 | 4081篇 |
| 2008年 | 9081篇 |
| 2007年 | 9706篇 |
| 2006年 | 9303篇 |
| 2005年 | 8961篇 |
| 2004年 | 8323篇 |
| 2003年 | 7809篇 |
| 2002年 | 7427篇 |
| 2001年 | 5084篇 |
| 2000年 | 5665篇 |
| 1999年 | 4346篇 |
| 1998年 | 805篇 |
| 1992年 | 2318篇 |
| 1991年 | 2078篇 |
| 1990年 | 2056篇 |
| 1989年 | 1761篇 |
| 1988年 | 1669篇 |
| 1987年 | 1573篇 |
| 1986年 | 1629篇 |
| 1985年 | 1528篇 |
| 1984年 | 1099篇 |
| 1983年 | 952篇 |
| 1979年 | 1262篇 |
| 1978年 | 850篇 |
| 1977年 | 817篇 |
| 1976年 | 785篇 |
| 1975年 | 934篇 |
| 1974年 | 1180篇 |
| 1973年 | 1227篇 |
| 1972年 | 1166篇 |
| 1971年 | 1123篇 |
| 1970年 | 1058篇 |
| 1969年 | 1127篇 |
| 1968年 | 1171篇 |
| 1967年 | 1031篇 |
| 1966年 | 922篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
21.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features 
下载免费PDF全文
下载免费PDF全文 22.
23.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献24.
25.
26.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献27.
28.
29.
30.